Edwards Lifesciences (EW) EBIAT (2016 - 2025)
Edwards Lifesciences (EW) has 17 years of EBIAT data on record, last reported at $81.9 million in Q4 2025.
- For Q4 2025, EBIAT fell 78.96% year-over-year to $81.9 million; the TTM value through Dec 2025 reached $1.1 billion, down 74.61%, while the annual FY2025 figure was $1.1 billion, 74.61% down from the prior year.
- EBIAT reached $81.9 million in Q4 2025 per EW's latest filing, down from $290.3 million in the prior quarter.
- Across five years, EBIAT topped out at $3.1 billion in Q3 2024 and bottomed at $81.9 million in Q4 2025.
- Average EBIAT over 5 years is $483.0 million, with a median of $353.7 million recorded in 2024.
- Peak YoY movement for EBIAT: soared 699.95% in 2024, then tumbled 90.54% in 2025.
- A 5-year view of EBIAT shows it stood at $335.3 million in 2021, then increased by 18.82% to $398.4 million in 2022, then fell by 7.2% to $369.7 million in 2023, then increased by 5.27% to $389.2 million in 2024, then tumbled by 78.96% to $81.9 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $81.9 million in Q4 2025, $290.3 million in Q3 2025, and $331.5 million in Q2 2025.